Ashi, Mohamad Omar Mami-Chouaib, Fathia Corgnac, Stéphanie
Published in
Exploration of Targeted Anti-tumor Therapy
Major advances in cancer treatment have emerged with the introduction of immunotherapies using blocking antibodies that target T-cell inhibitory receptors, such as programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), known as immune checkpoints. However, most cancer patients do not respond to immune checkpoint blockad...
Zang, Chaoran Zhao, Yan Liu, Guihai Li, Kang Qin, Ling Zhang, Yuewei Sun, Jianping Wang, Qi Ma, Liang Zhao, Peng
...
Published in
Frontiers in Immunology
Background Ablative therapy is a recommended treatment for hepatocellular carcinoma (HCC) not only for its effective eradication of tumors, but also for its induction of host immunity. However, the high 5-year recurrence rate after ablation underlines the poor understanding of the antitumor immunity response. Here, we investigated the effects of th...
Zhang, Jianying Guo, Xiangqian Jin, Bilian Zhu, Qing
Published in
Frontiers in Oncology
Luo, Manli Wu, Songmei Ma, Yan Liang, Hong Luo, Yage Gu, Wentao Fan, Lijuan Hao, Yang Li, Haiting Xing, Linbo
...
Published in
Frontiers in Genetics
Background: The aim of this study was to identify a panel of candidate autoantibodies against tumor-associated antigens in the detection of osteosarcoma (OS) so as to provide a theoretical basis for constructing a non-invasive serological diagnosis method in early immunodiagnosis of OS. Methods: The serological proteome analysis (SERPA) approach wa...
Arvedson, Tara Bailis, Julie M. Britten, Carolyn D. Klinger, Matthias Nagorsen, Dirk Coxon, Angela Egen, Jackson G. Martin, Flavius
T cell engagers (TCEs) are targeted immunotherapies that have emerged as a promising treatment to redirect effector T cells for tumor cell killing. The strong therapeutic value of TCEs, established by the approval of blinatumomab for the treatment of B cell precursor acute lymphoblastic leukemia, has expanded to include other hematologic malignanci...
Ren, Pengfei Wang, Keyan Ma, Jie Cao, Xiaoqin Zhao, Jiuzhou Zhao, Chengzhi Guo, Yongjun Ye, Hua
Published in
Journal of Hepatocellular Carcinoma
Purpose Ferritin is a protein that plays an important role in iron metabolism, it consists of two subunits: heavy chain (FTH) and light chain (FTL). Elevated expression of FTL is observed in multiple malignancies. Recent studies have found that the frequency of circulating autoantibody against FTL (anti-FTL) increased significantly in hepatocellula...
belousov, pavel v.
The Autoantibodies targeting Tumor-Associated Antigens (TAA-AAbs) emerge as a result of a variety of tumor-related immunogenic stimuli and may be regarded as the eyewitnesses to the anti-tumor immune response. TAA-AAbs may be readily detected in peripheral blood to unveil the presence of a particular TAA-expressing tumor, and a fair number of TAAs ...
kumai;, takumi
The success of the immune checkpoint blockade has provided a proof of concept that immune cells are capable of attacking tumors in the clinic. However, clinical benefit is only observed in less than 20% of the patients due to the non-specific activation of immune cells by the immune checkpoint blockade. Developing tumor-specific immune responses is...
Kono, Michihisa Komatsuda, Hiroki Yamaki, Hidekiyo Kumai, Takumi Hayashi, Ryusuke Wakisaka, Risa Nagato, Toshihiro Ohkuri, Takayuki Kosaka, Akemi Ohara, Kenzo
...
Published in
Oncoimmunology
Fibroblast growth factor receptor 1 (FGFR1) is overexpressed in multiple types of solid tumors, including head and neck squamous cell carcinoma (HNSCC). Being associated with poor prognosis, FGFR1 is a potential therapeutic target for aggressive tumors. T cell-based cancer immunotherapy has played a central role in novel cancer treatments. However,...
Berner, Fiamma Niederer, Rebekka Luimstra, Jolien J. Pop, Oltin Tiberiu Jochum, Ann-Kristin Purde, Mette-Triin Hasan Ali, Omar Bomze, David Bauer, Jens Freudenmann, Lena Katharina
...
Published in
Oncoimmunology
Immune checkpoint inhibitors (ICIs) have improved the survival of patients with non-small cell lung cancer (NSCLC) by reinvigorating tumor-specific T cell responses. However, the specificity of such T cells and the human leukocyte antigen (HLA)-associated epitopes recognized, remain elusive. In this study, we identified NSCLC T cell epitopes of rec...
